The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives (Q57926685)

From Wikidata

Revision as of 08:15, 31 May 2024 by ԱշբոտՏՆՂ (talk | contribs) (‎Added [hy] description: հոդված հրատարակված 2018 թվականին, based on en:article published in 2018)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

article published in 2018

Language	Label	Description	Also known as
English	The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives	article published in 2018

Statements

scholarly article

0 references

The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives (English)

0 references

behavioral neuroscience

0 references

Karl Martin Klein

object named as

Karl Martin Klein

3

0 references

Susanne Schubert-Bast

object named as

Susanne Schubert-Bast

1

0 references

Adam Strzelczyk

object named as

Adam Strzelczyk

6

0 references

2

object named as

Felix Rosenow

0 references

4

object named as

Philipp S. Reif

0 references

Matthias Kieslich

5

object named as

Matthias Kieslich

0 references

publication date

June 2018

0 references

Epilepsy Behavior

0 references

Tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

mTOR in Brain Physiology and Pathologies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Impaired synaptic plasticity in a rat model of tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Cognitive prognosis of patients with tuberous sclerosis complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Cognitive impairment in tuberous sclerosis complex is a multifactorial condition

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Influence of seizures on early development in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Clinical presentation and diagnosis of tuberous sclerosis complex in infancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Management of seizures in Lennox-Gastaut syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Tuberous sclerosis complex and the ketogenic diet

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Ketogenic Diet for the Management of Epilepsy Associated with Tuberous Sclerosis Complex in Children

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Rapamycin reduces seizure frequency in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Everolimus treatment of refractory epilepsy in tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Early control of seizures improves long-term outcome in children with tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Early Detection of Tuberous Sclerosis Complex: An Opportunity for Improved Neurodevelopmental Outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Regression of Neonatal Cardiac Rhabdomyoma in Two Months Through Low-Dose Everolimus Therapy: A Report of Three Cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Accelerated Cardiac Rhabdomyoma Regression with Everolimus in Infants with Tuberous Sclerosis Complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Regression of massive cardiac rhabdomyoma on everolimus therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Dramatic relapse of seizures after everolimus withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Long-term treatment of epilepsy with everolimus in tuberous sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Prospective clinical trials to investigate clinical and molecular biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2018.05.039

7 January 2021

Identifiers

10.1016/J.YEBEH.2018.05.039

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57926685&oldid=2169315435"